We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nanion’s SyncroPatch is Preferred Technology for Patch Clamp-Based HTS
Product News

Nanion’s SyncroPatch is Preferred Technology for Patch Clamp-Based HTS

Nanion’s SyncroPatch is Preferred Technology for Patch Clamp-Based HTS
Product News

Nanion’s SyncroPatch is Preferred Technology for Patch Clamp-Based HTS


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Nanion’s SyncroPatch is Preferred Technology for Patch Clamp-Based HTS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

According to a recent survey among automated patch clamp users, performed by HTStec Ltd., respondents favour Nanion’s instrumentation regarding cost, throughput, stability and support. Additionally, Nanion has the most appealing platforms for future purchase according to the survey.

With the introduction of the ion channel drug screening platform, the SyncroPatch 384/768PE, in 2013, Nanion became a major player in the high throughput screening (HTS) market. Nanion’s patch clamp-based HTS platform allows the screening of compound libraries of >100,000 substances, and facilitates a paradigm shift in drug discovery.

Instead of indirect approaches of the past, compound effects can be efficiently and accurately investigated for drug discovery, lead optimization and safety testing purposes using patch clamp, saving valuable time and minimizing the risk of false positives or negatives.

In the recent HTStec report on automated patch clamp (APC) instrumentation, aiming to comprehensively document current practices, preferences and metrics in ion channel drug screening using APC technology, Nanion stood out as the favored APC vendor, with the most appealing platforms for future purchase.

Dr. Niels Fertig, CEO of Nanion Technologies, says: “Since the launch of the SyncroPatch 384/768PE, there has been great interest in the platform, we clearly experience the market’s readiness for APC-based high throughput screening. We are very pleased with the outcome of the HTStec report, where the expanding installed base of our platforms confirms the trend presented in the report, and this not only in industrial settings. Contrary to what we initially expected, the SyncroPatch 384/768PE has also attracted academic scientists. The platform which will be installed at University College London later this month is one of multiple systems placed in a purely academic setting. This illustrates how versatility, high quality, and high throughput all coalesce in the SyncroPatch 384/768PE platform, making it attractive for both screening and research purposes.”

The SyncroPatch 384/768PE was developed in close collaboration with key customers in the pharmaceutical industry, and best-in-class robotics providers. This strategy has proven pertinent considering the quick development and roll-out, successful integration into HTS-environments and the rapidly growing installed base of the platform.

Advertisement